Full Press Release Details
Assembly Biosciences Reports First Quarter
2019 Financial Results and Recent Highlights
SAN FRANCISCO, May 9, 2019 - Assembly Biosciences,
Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV)
and diseases associated with the microbiome, today reported financial results for the first quarter ended March 31, 2019 and provided
"We are dedicated to increasing cure rates for individuals
with chronic HBV and were honored to have data highlighting our deep pipeline of novel core inhibitor candidates featured at The
International Liver Congress (ILC) last month, including our ABI-H0731 presentation as a Best of ILC' selection,"
said Derek Small, President and Chief Executive Officer. "We showed interim data from the ongoing Phase 2a trials of 731
demonstrating the potential of core inhibitors in combination with Nuc therapy to be the backbone of HBV cure regimens going forward,
along with updates on our next generation core inhibitor programs. Additionally, we initiated a Phase 1b trial for our first microbiome
clinical program in collaboration with Allergan, with ABI-M201 now being evaluated in ulcerative colitis patients."
Mr. Small continued, "Our progress this year has helped
us to attract development veterans to our leadership team to support both of our programs: Steven J. Knox as Senior Vice President
Clinical Development and David R. Houck, Ph.D., as Senior Vice President Product Development and Portfolio Management. These additions
reflect our continued evolution into a clinical-stage organization across both our HBV and microbiome programs, allowing us to
focus our resources on key pipeline priorities and improving our cash runway."
First Quarter 2019 and Recent Highlights
Anticipated Milestones and Events
Upcoming Conferences
First Quarter 2019 Financial Results
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral
core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program
is developing novel oral live synthetic biotherapeutic candidates with Assembly's fully integrated platform, including a
robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal
tract with the GEMICEL technology. For more information, visit assemblybio.com.
Forward-Looking Statements
The information in this press release contains forward-looking statements regarding future events, including statements about the
clinical and therapeutic potential of core inhibitors, the timing of the initiation of and the availability of data from our ongoing
and planned clinical trials and cash projections. Certain forward-looking statements may be identified by reference to a future
period or by use of forward-looking terminology such as "expected," "may," "will," "projected"
and "potential." Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained
in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual
results or developments may differ materially from those projected or implied in these forward-looking statements. These risks
and uncertainties include, among others: the components, timing, cost and results of clinical trials and other development activities
involving our product candidates (including those licensed by Allergan Pharmaceuticals International Limited); the unpredictability
of the preclinical and clinical development of our product candidates and of the duration and results of regulatory review of those
candidates by the FDA and foreign regulatory authorities; our anticipated capital expenditures and our estimates regarding our
capital requirements; and the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining
such rights from third parties. More information about the risks and uncertainties faced by Assembly are more fully detailed under
the heading "Risk Factors" in Assembly's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed
with the Securities and Exchange Commission. Except as required by law, Assembly assumes no obligation to update publicly
any forward-looking statements, whether as a result of new information, future events or otherwise.
and Vemlidy are registered trademarks of Gilead Sciences, Inc., or its related companies.
Assembly Biosciences, Inc.
| ASSEMBLY BIOSCIENCES, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| ($ in thousands except for share and per share amounts) | ||||||||
| March 31, | December 31, | |||||||
| 2019 | 2018 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 29,107 | $ | 41,471 | ||||
| Marketable securities | 164,429 | 176,609 | ||||||
| Accounts receivable from collaboration | 2,987 | 2,430 | ||||||
| Prepaid expenses and other current assets | 4,283 | 1,992 | ||||||
| Total current assets | 200,806 | 222,502 | ||||||
| Property and equipment, net | 2,079 | 557 | ||||||
| Operating lease right-of-use assets | 13,063 | - | ||||||
| Other assets | 1,661 | 3,348 | ||||||
| Indefinite-lived intangible asset | 29,000 | 29,000 | ||||||
| Goodwill | 12,638 | 12,638 | ||||||
| Total assets | $ | 259,247 | $ | 268,045 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 2,427 | $ | 3,693 | ||||
| Accrued expenses | 10,141 | 9,679 | ||||||
| Deferred revenue - short-term | 9,933 | 5,100 | ||||||
| Operating lease liabilities - short-term | 2,704 | - | ||||||
| Total current liabilities | 25,205 | 18,472 | ||||||
| Deferred rent | - | 108 | ||||||
| Deferred tax liabilities | 3,252 | 3,252 | ||||||
| Deferred revenue - long-term | 29,868 | 35,560 | ||||||
| Operating lease liabilities - long-term | 10,521 | - | ||||||
| Total liabilities | 68,846 | 57,392 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding | - | - | ||||||
| Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 25,549,757 and 25,495,425 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively | 26 | 25 | ||||||
| Additional paid-in capital | 559,453 | 552,762 | ||||||
| Accumulated other comprehensive loss | (239 | ) | (347 | ) | ||||
| Accumulated deficit | (368,839 | ) | (341,787 | ) | ||||
| Total stockholders' equity | 190,401 | 210,653 | ||||||
| Total liabilities and stockholders' equity | $ | 259,247 | $ | 268,045 |
| ASSEMBLY BIOSCIENCES, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||
| ($ in thousands except for share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2019 | 2018 | |||||||
| Collaboration revenue | $ | 3,885 | $ | 3,565 | ||||
| Operating expenses: | ||||||||
| Research and development | 22,704 | 14,541 | ||||||
| General and administrative | 9,517 | 5,696 | ||||||
| Total operating expenses | 32,221 | 20,237 | ||||||
| Loss from operations | (28,336 | ) | (16,672 | ) | ||||
| Other income (expenses) | ||||||||
| Interest and other income | 1,276 | 446 | ||||||
| Other income (expense), net | 1 | (23 | ) | |||||
| Total other income | 1,277 | 423 | ||||||
| Loss before income taxes | (27,059 | ) | (16,249 | ) | ||||
| Income tax benefit | 7 | - | ||||||
| Net loss | $ | (27,052 | ) | $ | (16,249 | ) | ||
| Other comprehensive (loss) income | ||||||||
| Unrealized gain (loss) on marketable securities, net of tax | 108 | (67 | ) | |||||
| Comprehensive loss | $ | (26,944 | ) | $ | (16,316 | ) | ||
| Net loss per share, basic and diluted | $ | (1.05 | ) | $ | (0.80 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 25,668,798 | 20,231,804 |